27-Mar-2026
Cantor Fitzgerald Sticks to Its Buy Rating for Elevance Health (ELV)
TipRanks (Wed, 25-Mar 8:27 AM ET)
Globe Newswire (Tue, 10-Mar 4:20 PM ET)
Business Wire (Tue, 3-Mar 10:00 AM ET)
Globe Newswire (Mon, 2-Mar 7:41 PM ET)
Business Wire (Thu, 26-Feb 3:02 PM ET)
ACCESS Newswire (Mon, 23-Feb 8:30 AM ET)
Globe Newswire (Thu, 5-Feb 10:46 AM ET)
Elevance Health Navigates Margin Pressures with Resilient Revenue Growth and Strong Cash Flow
Market Chameleon (Wed, 28-Jan 6:18 AM ET)
Market Chameleon (Wed, 28-Jan 2:14 AM ET)
Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook
Business Wire (Wed, 28-Jan 6:00 AM ET)
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Elevance Health trades on the NYSE stock market under the symbol ELV.
As of March 27, 2026, ELV stock price declined to $286.39 with 1,210,889 million shares trading.
ELV has a beta of 0.40, meaning it tends to be less sensitive to market movements. ELV has a correlation of 0.04 to the broad based SPY ETF.
ELV has a market cap of $63.21 billion. This is considered a Large Cap stock.
Last quarter Elevance Health reported $49 billion in Revenue and $3.33 earnings per share. This fell short of revenue expectation by $-161 million and exceeded earnings estimates by $.23.
In the last 3 years, ELV traded as high as $567.26 and as low as $273.71.
The top ETF exchange traded funds that ELV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ELV has underperformed the market in the last year with a return of -32.1%, while the SPY ETF gained +13.1%. In the last 3 month period, ELV fell short of the market, returning -17.7%, while SPY returned -7.9%. However, in the most recent 2 weeks ELV has outperformed the stock market by returning -1.8%, while SPY returned -4.0%.
ELV support price is $287.27 and resistance is $301.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELV shares will trade within this expected range on the day.